Lee DY, et al. - In young breast cancer patients, researchers assessed predictive factors for recovery of ovarian function after ovarian protection by GnRH agonist during chemotherapy by analyzing data of 105 young breast cancer subjects who were studied longitudinally after receiving GnRH agonist during cyclophosphamide-based chemotherapy for ovarian protection. The results obtained from this prospective cohort study indicate that pretreatment anti-Müllerian hormone (AMH) (3.26 ng/ml), age (33.9 years), pretreatment follicle-stimulating hormone (FSH) (5.5 IU/l), and tamoxifen use were useful predictors for AMH ≥ 1 ng/ml at 12 months after GnRH agonist. Patient and clinician decision-making regarding fertility preservation will support this finding.